Rockwood Strategic PLC Reports Strong NAV Growth and Outperforms Market Indices
Rockwood Strategic PLC's 21.1% NAV growth outperforms FTSE indices, with 54.5% 3-year returns. Insights on portfolio drivers and future opportunities.
This article covers information on Rockwood Strategic PLC.
LON:RKWA Stellar Year for Rockwood Strategic
Let’s cut straight to the chase: Rockwood Strategic has just delivered a masterclass in UK small-cap investing. Their latest RNS update reveals a fund firing on all cylinders, deftly navigating a choppy market while leaving benchmark indices eating dust. Here’s why this performance deserves your attention – and what it signals for savvy investors.
By the Numbers: Outperformance Writ Large
The headline figures are arresting:
- 21.1% NAV total return for FY2025 vs. -8.2% for the FTSE AIM All-Share
- 54.5% three-year NAV return dwarfing both FTSE Small Cap (-6.6%) and AIM (-34.6%)
- Shares consistently trading at premium (2.9% average), defying the investment trust discount curse
This isn’t just beating the market – it’s lapping it. The kicker? Rockwood achieved this while expanding its war chest, issuing 7.63m new shares and growing NAV to £96.6m. Scale matters in small-cap land, and they’re now playing in the sub-£250m market cap sweet spot with serious firepower.
The Portfolio: Stock-Picking Alchemy
Rockwood’s secret sauce lies in its concentrated bets on corporate transformations. Their top performers read like a playbook for active investing:
Star Turnarounds
- Funding Circle: Share buybacks and cost cuts post Rockwood’s activist engagement
- Filtronic: SpaceX contracts triggering profit upgrades – because when Elon calls, markets listen
- National World: Takeover approach validating management’s digital pivot
New Money Mavericks
- Capita: Betting on new management’s “root & branch” overhaul
- Vanquis Banking: Banking on (pun intended) new leadership’s recovery playbook
- Kooth: Mental health platform with global potential – classic inefficient market opportunity
This isn’t passive indexing – it’s surgical investing in special situations where Rockwood’s engagement can move the needle.
The Manager’s Gambit: Contrarian & Confident
Richard Staveley’s commentary crackles with conviction. Key takeaways:
- Sees current UK small-cap weakness (post-US tariff jitters) as generational buying opportunity
- Portfolio companies have “new management, clear plans, aligned incentives” – the holy trinity of turnarounds
- Warning shot across market’s bow: Expect “maelstrom of takeover bids” if valuations stay depressed
The cheeky namecheck of investing legends (Buffett, Munger et al) isn’t mere posturing – it’s positioning Rockwood as heir to the value investing throne. Bold? Absolutely. Unfounded? The track record suggests otherwise.
What This Means for Investors
Three compelling implications:
- Proof of concept: The concentrated, activist-tinged strategy works – and scales
- M&A optionality: With 62.9% of NAV in top 10 holdings, any takeover could turbocharge returns
- Contrarian signal: When managers cite “material buying opportunity” while putting cash to work (net £1m), smart money listens
As Staveley notes, the real test isn’t today’s price action – it’s where these companies will be in 3-5 years. For investors tired of passive platitudes, Rockwood offers something refreshing: a properly active approach with skin in the game. The premium rating suggests the market’s starting to notice. Will you?
Disclosure: This is analysis, not advice. But if you’re not scrutinising funds that triple benchmarks while trading at premiums… well, as Buffett might say, you’re dancing without a partner.
Related
Keep reading
Investing
Ten Technologies Preliminary Results 2026: Record EBITDA and Member Growth
Ten Technologies delivered record 2026 results as active members rose 23% and adjusted EBITDA increased 10% to £16.1 million.
JoshuaNovember 11, 2026
Investing
Winvia Entertainment completes The Online Giveaway Guys acquisition
Winvia Entertainment has completed its purchase of The Online Giveaway Guys' business and key assets, excluding liabilities, cash and receivables.
JoshuaNovember 10, 2026
Investing
RUA Life Sciences reaches positive adjusted EBITDA as Structural Heart spin-out reshapes the group
RUA Life Sciences expects £5.5 million revenue and £0.3 million adjusted EBITDA, but ABISS weakness and lower cash warrant attention.
JoshuaNovember 9, 2026
Last updated
Category
InvestingLikes
Star Rating
No ratings yet
Comments
No comments yet - start the conversation.